Despite being part of the EULAR/ACR criteria, the clinical utility of ANA and anti-DNA assays in SLE patients is highly debated due to their inconsistency and non-resolution of their pathogenic roles (12, 15–18). This evidence concerns the gene BTG3 and systemic lupus erythematosus.